Influenza A virus H3N2 hemagglutinin-specific antibody (H3N2 HA Ab)

Human B-cell receptors (BCRs) and circulating antibodies specific for H3N2 hemagglutinin (HA) are the primary components of the adaptive immune system responsible for protecting against H3N2 influenza viruses. These antibodies recognize and bind to the HA glycoprotein on the viral surface, which is essential for the virus to attach to and enter host cells (Nature Communications, 2019, 10:3720). The most potent antibodies typically target the receptor-binding site (RBS) on the globular head of the HA, effectively neutralizing the virus by preventing its attachment to sialic acid receptors on the respiratory epithelium (Journal of Virology, 2014, 88:12). Other antibodies may target the more conserved stem region of the HA, preventing the pH-dependent membrane fusion required for viral genome release into the cytoplasm. The population of these antibodies in an individual is heavily influenced by their history of infection and vaccination, a phenomenon known as antigenic seniority or original antigenic sin (PNAS, 2016, 113:14574-14581). Because H3N2 viruses undergo rapid antigenic drift, the specificity of the circulating antibody repertoire must be updated through annual seasonal influenza vaccinations to maintain protective efficacy (Science, 2004, 305:371-376). Therapeutic research in this area focuses on the isolation of broadly neutralizing antibodies (bnAbs) that can provide cross-reactive protection against diverse H3N2 strains and other influenza subtypes.

Other names

Human B-cell receptors specific for H3N2 hemagglutininAnti-H3N2 hemagglutinin antibodiesH3N2 neutralizing antibodiesH3N2 HA-specific BCRInfluenza A H3N2 HA antibodies

Neutralization of viral entry by blocking the hemagglutinin receptor-binding site or inhibiting pH-dependent membrane fusion.